CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞淋巴瘤的进展及 CNS 受累的危险因素
英文原题：Advances in T-cell lymphomas and risk factors for CNS involvement.
查看英文原题
Advances in T-cell lymphomas and risk factors for CNS involvement.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T细胞淋巴瘤（TCLs）是一种罕见的异质性血液系统肿瘤，对传统细胞毒性化疗反应不佳，且尚无普遍接受的治疗金标准。中枢神经系统（CNS）受累较为罕见，通常与不良预后和发病率增加相关。近年来，对CNS复发临床病理危险因素的识别进行了评估，预测性多变量模型的开发仍是一个活跃的研究领域。本综述总结了原发性和复发性TCL伴或不伴CNS受累的流行病学、危险因素和治疗，并描述了已探索用于治疗TCL的多种治疗策略，包括表观遗传调控、CAR-T 细胞疗法和免疫治疗。
展开英文摘要原文
T-cell lymphomas (TCLs) are rare heterogenous hematologic neoplasms that exhibit poor response to traditional cytotoxic chemotherapy and have no universally accepted gold standard of treatment. Central nervous system (CNS) involvement is rare and generally associated with poor prognosis and increased morbidity. The identification of clinicopathologic risk factors for CNS relapse has been evaluated in recent years, and the development of predictive multivariable models remains an active area of study.
This review summarizes the epidemiology, risk factors and treatment of both primary and relapsed TCL with and without CNS involvement and describes multiple therapeutic strategies that have been explored for the treatment of TCLs including epigenetic modulation, chimeric antigen receptor T-cell therapy, and immunotherapy.
论文信息
- 作者
- Elghawy O、Swami N、Hing ZA、Barta SK
- 单位
- Division of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.United States
- 文献类型
- 综述
- 期刊
- Leukemia & lymphoma2025 Sep
- 原文标识
- PubMed 40590768 · DOI 10.1080/10428194.2025.2510524